Category: NDA

FDA Approves First Gene Therapy for Aromatic L-amino Acid Decarboxylase (AADC) Deficiency: A Landmark in Rare Disease Treatment

IntroductionThe U.S. Food and Drug Administration (FDA) has recently approved a ground-breaking gene therapy for the treatment of Aromatic L-amino Acid Decarboxylase (AADC) deficiency, marking a significant advancement in the field of genetic disorders. This

Read More

Important Regulatory Changes in USFDA for Pharma Companies in 2024 to File an NDA

The USFDA’s 2024 regulatory changes At Vigilare Biopharma, we understand the complexities and challenges that pharmaceutical companies face when navigating the ever-evolving regulatory landscape. The USFDA’s 2024 regulatory changes reflect a significant shift towards enhancing

Read More